Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
← catalyst calendarNCT07282587 · readout in 848 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-02 | actual | When the study began enrolling |
| Primary completion | 2028-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Pheochromocytoma and Paraganglioma
- PCPG
Interventions
- Drug: ONC206
- Drug: ONC206: Dose 1
- Drug: ONC206: Dose 2
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured Up to 36 months.
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed